Sichuan Clover Biopharmaceuticals
Latest round
- Series C
Last raised
- Feb 2021
Total raised
- $297M
Investors
- 11
About Sichuan Clover Biopharmaceuticals
, is a global clinical-stage biotechnology company committed to developing novel vaccines and biological therapeutic candidates to address life-threatening diseases and public health threats. The company has established a partnership with CEPI and Dynavax to deliver a safe and effective COVID-19 vaccine to countries and regions around the world affected by the COVID-19 pandemic. The company has a commercial manufacturing facility in Chanxing and Chengdu, suppling R&D and clinical programs. In 2021, Sichuan Clover Biopharmaceuticals, Inc. The company’s flagship Trimer-Tag© technology is a product development platform for the creation of vaccines and therapies. This technology helps to trimerize any protein of interest and target a broad spectrum of naturally trimerization-dependent disease and biological targets. Clover produces covalently-trimerized fusion proteins to target previous pathways and has also developed SCB-2019 (CpG 1018/Alum), a vaccine candidate for SARS-CoV-2 infections. Additionally, the company is conducting vaccine discovery programs for other infections including rabies, RSV, influenza, and HIV. Apart from the COVID-19 vaccine, Clover has designed and developed SCB-313 for the treatment of intracavitary malignancies including malignant ascites (MA), malignant pleural effusion (MPE), and peritoneal carcinomatosis (PC), as well as additional cancer indications; along with SCB-808 for rheumatic diseases, SCB-420 for the treatment of certain large market ophthalmologic diseases, including wet age-related macular degeneration (wAMD), and SCB-219 for CIT(chemotherapy-induced thrombocytopenia) and ITP (immune thrombocytopenic purpura). The company plans to commercialize SCB-2019 (CpG 1018/Alum) as one of the first protein-based COVID-19 vaccines and subsequently submit applications to the EMA, the NMPA, and the WHO by the second half of 2021 and launch the product by the end of 2021. Clover also plans to capture a market of 15 billion doses required through 2026. The firm also plans to submit SCB-808 for approval to the NDA and NMPA in 2022.
Who invested in Sichuan Clover Biopharmaceuticals
11 investors across 4 rounds
See all investors in Sichuan Clover Biopharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sichuan Clover Biopharmaceuticals
Who invested in Sichuan Clover Biopharmaceuticals?
Sichuan Clover Biopharmaceuticals has 11 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sichuan Clover Biopharmaceuticals raised?
Sichuan Clover Biopharmaceuticals has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Sichuan Clover Biopharmaceuticals last raise money?
Sichuan Clover Biopharmaceuticals's most recent round on record is a Series C, in Feb 2021.
What does Sichuan Clover Biopharmaceuticals do?
, is a global clinical-stage biotechnology company committed to developing novel vaccines and biological therapeutic candidates to address life-threatening diseases and public health threats.
Where is Sichuan Clover Biopharmaceuticals headquartered?
Sichuan Clover Biopharmaceuticals is headquartered in Chengdu, China.
Which VCs invest in companies like Sichuan Clover Biopharmaceuticals?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Sichuan Clover Biopharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Sichuan Clover Biopharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.